DIN BELLE, David,MAKELA, Mikko,PASSINIEMI, Mikko,PIETIKAINEN, Pekka,RUMMAKKO, Petteri,TIAINEN, Eija,VAISMAA, Matti,WOHLFAHRT, Gerd
申请号：
PE2019001297
公开号：
PE20191137A1
申请日:
2017.12.21
申请国别(地区):
PE
年份:
2019
代理人:
摘要：
REFERENCES DERIVED FROM PIRANO FROM FORMULA (I) WHERE R1, R2, R3, R4, R5, R23, R24, L, RINGS A AND B ARE AS DEFINED IN THE DESCRIPTION. THEY ARE PREFERRED COMPOUNDS: 2- (ISOINDOLIN-2-ILMETIL) -5 - ((4- (PIRROLIDIN-1-ILSULFONIL) BENCIL) OXI) -4H-PIRAN-4-ONA； 4 - (((6- (ISOINDOLIN-2-ILMETIL) -4-OXO-4H-PIRAN-3-IL) OXI) METHYL) -N-METHYLBENZENE SULFONAMIDE； AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF CYTOCHROME P450 MONOOXIGENASA 11A1 (CYP11A1) BEING USEFUL IN THE TREATMENT OF CANCER DE PROSTATA, CANCER DE MAMASE REFIERE COMPUESTOS DERIVADOS DE PIRANO DE FORMULA (I) DONDE R1, R2, R3, R4, R5, R23, R24, L, LOS ANILLOS A Y B SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: 2-(ISOINDOLIN-2-ILMETIL)-5-((4-(PIRROLIDIN-1-ILSULFONIL)BENCIL)OXI)-4H-PIRAN-4-ONA； 4-(((6-(ISOINDOLIN-2-ILMETIL)-4-OXO-4H-PIRAN-3-IL)OXI)METIL)-N-METILBENCENOSULFONAMIDA； ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL CITOCROMO P450 MONOOXIGENASA 11A1 (CYP11A1) SIENDO UTILES EN EL TRATAMIENTO DE CANCER DE PROSTATA, CANCER DE MAMA
